545 studies on the hirudins are being carried out to test their efficacy as surgical and interventional anticoagulants as replacements for heparin. However. the need for a proper antagonist is one of the limiting factors for the optimal development of hirudin in this indication. Several of the synthetic thrombin inhibitors are also being developed for oral use for the prophylaxis of DVT in surgical patients. Since the therapeutic index of thrombin inhibitors is narrower than that of heparin. this route may not be an optimal approach for the development of these agents. Despite several unresolved developmental issues. the thrombin inhibitors provide a useful alternative to heparin anticoagulation and may prove to be useful in validated clinical use. Key Words: Antithrombin-Anticoagulants-Hirudin-Heparin.
as kallikrein (6) , factor XlIa (7) , and activated protein C
(1,8) also promote the activation of plasminogen. Some of the synthetic thrombin inhibitors are capable of producing the inhibition of these enzymes (9) (10) (11) . Thus, physiologic and pharmacological fibrinolysis can be compromised. Thrombin inhibitors, therefore, exert a complex effect on the coagulation network and should be carefully evaluated in various clinical trials.
In the absence of heparin, thrombin is marginally neutralized by endogenous inhibitors such as heparin cofactor II (He II) and antithrombin III (AT III), but because of their mass, these inhibitors are not capable of effectively neutralizing clot-bound thrombin. However, the lower mass of thrombin inhibitors allows these agents to penetrate the thrombus and inhibit the thrombin contained within to control further enlargement of the thrombus. Thus, smaller molecular weight thrombin inhibitors are capable of producing the inhibition of clotbound thrombin and may be more effective than heparin.
OVERVIEW OF THROMBIN INHIBITORS
Direct thrombin inhibitors can be classified according to source, structure, recombinant and synthetic type, and interaction with substrates. Some of these agents are directed against the catalytic site of thrombin while others bind to the exosites of thrombin. In addition, some are reversible inhibitors while others arc irreversible. A list of currently available site-directed thrombin inhibitors is given in Table I . These agents are also depicted in Fig. I .
Among the natural thrombin inhibitors, hirudin is one of the most potent and is found in the saliva of the leech Hirudo medicinalis. It is a single polypeptide chain of 65 amino acid residues, stabilized in a characteristic conformation by three disulfide bonds (12) . Hirudin and its variants have been produced by recombinant technology (13) (14) (15) (16) , Point mutations to develop variant forms of hirudin have been used ( 17) . More recently, polyethylene glycol coupling of r-hirudin, to develop longer lasting agents, has been accomplished (15.18) . Several experimental and clinical trials have shown that polyethylene glycol coupling of hirudin produces an increase in the efficacy of the drug. Various derivatives of hirudin arc being aggressively developed for several clinical indications.
Coupling of peptides that mimic the carboxyterminal of hirudin to peptides that arc specific for inhibition of the catalytic site of thrombin (D-Phe-Pro-Arg) has led to the development of a series of chimeric molecules termed hirulogs, in which the amino terminus consists of the catalytic site-directed peptides, while the carboxyterminus consists of the 12 terminal residues of hirudin. The two moieties are linked together by a bridge of glycine residues of variable lengths (19, 20) . Thus, hirulogs inhibit thrombin by binding to its catalytic site and its anion binding exosite, thus conferring specificity to these molecules for thrombin. Hirulog-I has been developed aggressively for several cardiovascular indications (21) (22) (23) . However, its superiority over heparin has not been established.
Antithrombin Agents
A novel synthetic thrombin inhibitor, CVS#995 (24), comprised of 19 amino acids, in which recognition sequences for the catalytic and primary exosite binding domains of thrombin have been linked by a transition state analog has also been reported (24) . The K, value for thrombin is in the pM range for this slow and tight binding thrombin inhibitor. When compared to hirulog-I, this agent is superior at inhibiting platelet aggregation and venous thrombosis in a rat model (24) .
One of the building blocks used to develop synthetic inhibitors is arginine with optimal C and/or N-terminal modifications. Many of these agents have been found to be highly toxic due to inhibition of butyl cholinesterase (25) . The introduction of a COOH group on the carboxyterminal results in decreased affinity for butyl cholinesterase (and therefore less toxicity). After further modifications an isomer called argatroban (MD805 or MC19 (38) has been generated as a selective inhibitor of thrombin (K, = 0.019 f.1M) (26) . This compound also has a sizeable affinity for trypsin (K, = 5.0 f.1M) (25) . It acts by directly inhibiting thrombin and preventing it from acting in the coagulation and fibrinolytic systems (27) (28) (29) , Argatroban is effective in preventing thrombus formation in various unimal models at low concentrations (> I f.1M) (25, 27) . This compound is being tested clinically for several indications (30) (31) (32) ,
With the knowledge of the primary structure of serine proteases and the identification of their proteolytic activation cleavage sites, specific chromogenic substrates for thrombin have been developed by synthesis of pep-tides mimicking the amino acid sequence adjacent to the substrate's cleavage site and attaching a paranitroaniline (pNA) group on the carboxyterminus of these peptides (9) . A comprehensive survey of the effects of many peptide inhibitors belonging to various classes, on a spectrum of serine proteases using clotting and novel amidolytic systems, has been completed by Fareed et al. (33) .
Several tripeptide aldehydes containing arginine have been developed as the first reversible peptide thrombin inhibitors. The prototype compound to be synthesized is D-Phe-Pro-Arg-H (GYKI-14166) (34) , which although a very selective and potent inhibitor of thrombin. is very unstable in a neutral aqueous solution where it cyclizes and is inactivated. To prevent cyclization, a derivative has been synthesized with a protective amino terminal t-butyloxycarbonyl (Boc) group: Boc-D-Phe-Pro-Arg-H (GYKI 14451) (35) . This compound is more stable than its parent compound but is not as specific for thrombin since it inhibits plasmin as well. To achieve compounds that are stable and specific for thrombin. a series of Nalkyl derivatives have been synthesized (a basic amino terminus promotes thrombin specificity) and from this series the methyl derivative D-MePhe-Pro-Arg-H (GYKI 14766) (36) (37) (38) has been found to be as potent and selective a reversible inhibitor of thrombin as the prototype aldehyde. The K, for the aldehyde derivatives is around 0.1 f..LM. All three aldehydes are effective antithrombotics in various animal models. One of these agents, efegatran (D-MePhe-Pro-Arg-H), has undergone clinical trials for prevention of reocclusion during interventional cardiovascular procedures.
Peptides of arginine chloromethyl ketones correspond to the primary structure of physiologic substrates of target proteases (39) . These agents have been used in biochemical studies of thrombin and hemostasis and in pharmacological studies. The toxicity of the tripeptide chloromethyl ketone D-Phe-Pro-ArgCH 2CI (PPACK) is species dependent. The antithrombotic effects of this tripeptide derivative examined in various animal models (rats, dogs, and rabbits) have shown in all studies to be an effective anti thrombotic after intravenous and subcutaneous administration.
Tripeptide derivatives with a-nitrile groups have been synthesized as competitive inhibitors of thrombin. The peptide derivative D-Phe-Pro-Arg-CN (40) has proved to be a potent competitive inhibitor of thrombin with a K, == 0.7 f..LM. This nitrile derivative is also an effective antithrombotic in various rat models of thrombosis.
The search for selective and potent inhibitors of thrombin has led to the development of three more classes of reversible tripeptide inhibitors: (a) trilluoromethyl ketones: the representative compound D-Phe-Pro-Arg-CF J (41) with a K, in the nM range; (b) a-aminophosphonic acid tripeptide derivatives with Kjs in the nM range (42) : these compounds form a new group of thrombin inhibitors since they have only neutral side chains; and (c) o-aminoboronic acid derivatives (43) . The boronic acid derivatives have been first developed as inhibitors of elastase and chymotrypsin. So, to develop a compound that would be specific for thrombin, the arginine in the sequence D-Phe-Pro-Arg has been substituted with its boronic acid derivative. This has led to the syn- Thrombin inhibitors derived from boronic acid lack specificity for thrombin. In an attempt to overcome this, the C terminal of the tripeptides has been extended (43) . However. the resulting compounds still lack in specificity for thrombin. Tapparelli et al. (44) have further modified these compounds by replacing the boroArg in the third position (corresponding to the S I pocket site of thrombin) with a neutral boron containing moiety. The compound Z-D-Phe-Pro-boroMpgCJl)H I 6 has a lower K, for thrombin (8.9 nM) than its predecessors. but the specificity for thrombin is improved (44) . However. this compound is a weak anticoagulant in the global clotting tests and does not inhibit thrombin-induced platelet aggregation in vitro or in vivo. While it is known that all of these antithrombin agents are potent thrombin inhibitors, little attention is paid to their mode of inhibition, which may be important in the efficacy of their anticoagulant and anti thrombotic effects. Since these new thrombin inhibitors vary in their mechanism of action in inhibiting thrombin. it is likely that they also differ in their actions in the coagulation cascade and the feedback mechanisms involved. Despite the fact that nonspecific thrombin inhibitors such as Ac-D-Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H are known to inhibit several of the fibrinolytic enzymes, systematic studies on their in vivo actions on the fibrinolytic/thrombolytic processes are limited. Although the majority of published experimental studies suggest no interference or even enhancement of thrombolysis by thrombin inhibitors. recent reports from clinical investigations are suggestive of fibrinolytic deficit produced by some of these agents (22) . These observations are supported by studies exploring the anti fibrinolytic effects of several thrombin inhibitors in vitro and in vivo in a recent publication (10) .
Aptamers are oligonucleotides (double-or singlestranded DNA. or single-stranded RNA) that act directly on thrombin. Thirty-two such aptamers have been recently isolated as inhibitors of thrombin with binding affinities in the range of 20-200 nM (45) . One of the most potent aptamers has been found to interact with the eli" Appl Thrombosis/Hemostasis. Vol, 5. Suppl, I. IWCJ anion binding exosite of thrombin, so that it competes with substrates that interact with that specific site, such as fibrinogen and thrombin platelet receptors (46, 47) . This aptamer has been shown recently to reduce arterial platelet thrombus formation in an animal model and inhibit clot-bound thrombin in an in vitro system (48). Recently, a second pool of aptamers with a different sequence composition than the first class, incorporating modified bases, has been isolated and has shown promising anticoagulant activities (49) . Another recent development in the area of oligonucleotide inhibitors of thrombin has been the isolation of two RNAs that bind thrombin with high affinity (Kd in the nM range). These oligonucleotides have been shown to inhibit fibrinogen clotting in an in vitro test (49) .
The development of oral thrombin inhibitors is somewhat slow due to the limited bioavailability of these agents. Pharmaceutical companies have initiated the development of oral thrombin inhibitors. Currently, several of these agents are in various phases of clinical trials. Most of the oral thrombin agents represent a peptidomimetic type of inhibitor. The bioavailability of these agents varies from 5% to 20%. Unlike the orally active glycoprotein (GP) lib/IlIa inhibitors, which are mostly prodrugs, the oral antithrombin drugs arc active thrombin inhibitors and do not require metabolic transformation after their absorption. The relative inhibitory potency of these agents is also variable. However, these agents exhibit comparable antithrombin effects to those observed with the intravenously active antithrombin agents.
It has been suggested that the oral antithrombin agents may be of use in outpatient/extended management of arterial and venous thromboses. Some investigators have equated these agents to oral anticoagulant therapy. However, the mechanisms of these two types of drugs are quite different.
While the oral thrombin inhibitors offer an attractive approach in the management of thrombotic disorders, there are several problems associated with their development. Some of these arc cited in the following.
I. Marked intraindividual variability in absorption (age,
gender, circadian factors). 2. Influence of food and drug intake on absorption.
Physiologic factors influence gastrointestinal (GI)
function. 4. Potential metabolic transformation during GI passage.
All of the above factors contribute significantly to the pharmacodynamic profile of these drugs. In addition, drug interactions will markedly influence the overall pharmacodynamics of these agents. It is likely that formulations may help alleviate some of these problems. However, because of the narrow therapeutic index, careful dosing will be needed.
The has been primarily based on the use of heparin as an anticoagulant in various indications. It is evident that various thrombin inhibitors represent a diverse variety of synthetic and recombinant agents, whose biochemical and pharmacological profiles differ significantly from that of heparin. A systematic approach to investigate these agents on the basis of their own chemical structure and projected pharmacological properties, using structure-activity relationship concepts, has not been made.
The cumulative antithrombin and anticoagulant properties of these agents should be taken into consideration along with other expected vascular and pharmacological effects of these agents. Currently, hirudin, hirulog-l, inogatran, napsagatran, melagatran, and argatroban are being developed for various indications in vascular and cardiovascular areas. Efegatran was initially developed for interventional cardiovascular indications; however, its development is on hold at this time. The only consideration for dosage and pharmacological effects have been the anticoagulant response as measured by the activated clotting time (ACT) or the activated partial thromboplastin time (aPTT). Because of a lack of pharmacological data, additional effects of these agents on other components of the hemostatic system have not been taken into account. To address some of these issues, a series of experiments have been designed to profile some of the available thrombin inhibitors to determine the impact of nonthrombin mediated effects of these agents.
CLINICAL APPLICATION OF ANTITHROMBIN DRUGS
Considering the crucial role of thrombin in thrombotic and cardiovascular events, it was initially thought that the inhibition of thrombin would be an efficient way to control the occlusive/thrombotic cardiovascular processes. In addition, several limitations of heparin and low molecular weight heparin were considered. These included (a) a narrow therapeutic window (wide variation in the pharmacologic results), (b) an endogenous modulation by proteins and platelet factor 4, (c) the inability to inhibit clot-bound thrombin and factor Xa, (d) heparininduced thrombocytopenia, (e) bleeding, and (f) osteoporosis.
For the above reasons, various thrombin inhibitors such as hirudin, polyethylene glycol coupled hirudin (PEG hirudin), hirulog, and argatroban were developed for various clinical indications. Several other thrombin inhibitors such as efegatran, napsagatran, inogatran, and melagatran were also used in limited clinical trials. Currently, a strong thrust in the clinical development of hirudin, PEG-hirudin, and argatroban is evident. These clinical developments have been recently reviewed (50) (51) (52) (53) (54) . A r-hirudin preparation is currently approved ill Someof the European countries for the use as an alternate anticoagulant in patients with heparin-induced thrombocytopenia (HIT). This product is developed for the HIT indication by Hoechst-Behring, Germany and is sold as Refludan®. Another r-hirudin was initially developed for various coronary syndromes by former Ciba Giegy and is currently managed by the newly formed company Novartis (Ntirnberg, Germany) under the trade name of Re-vasc®. While argatroban is available in Japan for various indications, this drug has undergone an extensive clinical trial in the management of HIT. This drug is currently developed by Texas Biotechnology Corp. (Houston, TX, U.S.A.) under the name of Novastan®.
To validate the hypothesis that direct thrombin inhibitors are superior to heparin in acute ischemic syndromes, several clinical trials (Global Use of Strategies to Open Occluded Coronary Arteries [GUSTO] and Thrombolysis and Thrombin Inhibition in Myocardial Infarction [TIMI]) have been completed recently (50, 51, 55, 56) . The combined data from the GUSTO-lIb and TIMI-9B trials revealed a 13% reduction in reinfarction at 30 days, but failed to demonstrate a superior efficacy over heparin in terms of mortality or on the combined endpoint (death Or nonfatal myocardial infarction) (53) . These events Were 10.8% for hirudin and 10.0% for heparin. Higher bleeding was observed with hirudin than with heparin. The cumulative outcome of the trial was rather disappointing and did not validate the hypothesis that thrombin inhibitors result in a better clinical outcome. A more Optimized clinical trial may help in providing additional data to support this hypothesis.
More recently, another study on the use of another hirudin (desirudin) preparation has been published (57) . This study (OASIS-I) used a slightly modified dosage of hirudin. A significant reduction in the combined incidence of death, myocardial infarction, and revascularization was noted at 7 days. However, the bleeding was still high. A larger randomized trial with a longer follow-up has been designed (OASIS-II). Because this trial will use an optimized dosage of hirudin, a better clinical outcome is expected.
As discussed earlier, hirulog is a 20-amino acid synthetic peptide that directly inhibits clot-bound thrombin. This product was developed by Biogen (Cambridge, MA, U.S.A.) under the name bivalirudin. The Hirulog Early Reperfusion trial (HERO) tested the efficacy of two hirulog protocols for early and complete flow of the infarct-related artery, and the relative safety of this drug With heparin (58) . Hirulog showed an increase in the TIMI grade 3 patency at 90 minutes after the administration of streptokinase. Additional studies to test this drug in a large trial are planned. Hirulog was also used in a deep vein thrombosis (DVT) prophylaxis trial and showed efficacy in this indication. More recently, Bio-gen has sublicensed this drug to the Medicines Company (Cambridge, MA, U.S.A.) for further development.
In the United States initial trials on argatroban (No-vastan®) were carried out on patients with unstable anginalnon-Q-wave myocardial infarction (59) . The initial results from this study were somewhat disappointing. Argatroban was also studied as an adjunct anticoagulant with thrombolytic therapy (alteplase) in 112 patients with acute myocardial infarction (60) . In this study, no significant differences were noted between argatroban and heparin. More recently, argatroban has been used in percutaneous transluminal coronary angioplasty (PTCA) (61, 62) . Figure 2 depicts the clinical development of argatroban as an example of the use of antithrombin agents in various clinical conditions. This agent has been tested in various clinical trials as an anticoagulant for PTCA, stenting, and other percutaneous interventions. In addition, this drug has been used in the management of thrombotic stroke in Japan. Continuous infusion of argatroban has been used to provide therapeutic anticoagulation in heparin compromised patients.
Thrombin inhibitors such as hirudin and hirulog have also been used for the management of postoperative venous thrombosis after hip or knee surgery (63) (64) (65) . Re-vasc® has been compared with unfractionated heparin and enoxaparin (a low molecular weight heparin) in the prophylaxis of DVT after total hip replacement. In these studies 15 mg b.i.d, of Revasc® provided better outcome than heparin or enoxaparin. Bivalirudin has also been tested in the prevention of postoperative thrombosis at 5 dosages (0.3-1.0 mg/kg) in various regimens. In this study of administration (postoperative), a 1.0 mg/kg bivalirudin t.i.d, subcutaneous was found to be safe and efficacious after major hip or knee surgery. The dosage of bivalirudin was relatively high in this study in comparison to the Revasc® studies. A recent study has re- ported on the comparative efficacy of a novel synthetic inhibitor of thrombin (napsagatran, Ro 46-6240) in the treatment of proximal vein thrombosis (66) . The results suggest that napsagatran treatment was as effective as heparin.
Besides the clinical applications in the coronary syndromes and DVT prophylaxis, thrombin inhibitors have also been used in the management of HIT. Currently, a r-hirudin preparation namely Refludan® (Aventis, Bridgewater. NY, U.S.A.) has been approved for clinical use in Europe. Additional clinical trials on this product are currently ongoing in various countries. Patients who develop HIT and require anticoagulation can be treated with antithrombin agents such as hirudin. In addition to hirudin, argatroban has also been extensively tested for its efficacy in HIT (62) .
At the present time, the most promising class of drugs for the initial treatment of patients with HIT antibody is the direct thrombin inhibitors. Hirudin and argatroban are currently in phase II and III development in the United States. These drugs offer the best alternatives for a prompt medical solution to the prophylactic treatment of HIT because they have no structural similarity to heparin and therefore do not cross-react with the HIT antibody. The thrombin inhibitors do not cross-react in a HIT-positive assay system. Recently, three individual case reports of HIT patients being successfully treated with hirulog were published and other successfully completed compassionate-use cases at our hospital strongly support this. Hirulog and argatroban offer an additional advantage in that the level of anticoagulation can be monitored with standard aPTf testing.
Argatroban has been shown not to cross-react with HIT antibody using in vitro platelet activation testing and in the clinical setting (62) . Argatroban is currently available under investigational protocol in the Unites States and, therefore, represents the most practical option for treatment of HIT at this time. The other direct thrombin inhibitors may also be good treatment options for HIT patients. Hirudin has become available in Germany for treatment of HIT patients.
The decision to treat patients prophylactically with direct thrombin inhibitors can be guided by the division of HIT patients into three groups. The first group consists of patients given heparin for documented clinical thrombosis. such as DVT, pulmonary embolism. unstable angina. myocardial infarction. and peripheral arterial thrombosis, who then develop HIT antibodies. These patients have a clear indication for anticoagulation and should be treated with thrombin inhibitors until adequate laboratory evidence of anticoagulation with warfarin can be documented.
The second group consists of HIT patients-who have no documented thrombosis but require long-term oral anticoagulation for prophylaxis. These include patients cu« ,II'I'I Throtnbosis/llrmostusis, Vol. 5. SIII'pl. I. 1'i'J9 with mechanical prosthetic valves. atrial fibrillation, and underlying hypercoagulable states. The ideal management strategy for these patients is to initiate oral anticoagulation while maintaining therapeutic levels of anticoagulation with an intravenous thrombin inhibitor. Once the international normalized ratio (INR) for warfarin is stable in the therapeutic range. the intravenous thrombin inhibitor can be tapered and finally discontinued.
The third group of HIT patients who present a management dilemma consists of those who have no documented thrombus and have no coincident condition that requires chronic anticoagulation. The literature to date suggests that patients with documented HIT antibody carry a 35% probability of developing a clinically significant thrombotic event during their hospitalization. Warkentin's observation with screening venography that nearly all the patients with HIT had at least subclinical venous thrombosis suggests that the probability of thrombosis in HIT patients may be even higher. In addition, it has been observed that an average of approximately two thrombotic events per heparin-induced thrombocytopenia thrombosis syndrome (HIlTS) patient occurs. Finally. a number of reports suggest that patients who develop HIlTS have a mortality of 25%--30%. The high probability of developing thrombosis in HIT patients, combined with the extreme mortality once HIlTS develops, has led to our bias for prophylactic treatment of HIT patients despite the lack of other indications for anticoagulation. Our current approach is initiation of a thrombin inhibitor while titrating warfarin to therapeutic levels of anticoagulation. The thrombin inhibitors are initiated with low levels of anticoagulation until the thrombocytopenia resolves. Once platelet counts exceed 100.0001Il-L, warfarin anticoagulation is initiated. Lowdose aspirin is added to the regimen once warfarin is therapeutic and the thrombin inhibitor is discontinued. This regimen is continued until laboratory evidence is provided that the HIT antibody can no longer be detected. Newly developed thrombin inhibitors are currently useful in the management of heparin compromised patients. However. each of the thrombin inhibitors should be carefully developed for this syndrome.
Despite major development in the use of antithrombin agents. several issues remain unresolved. These include dosing for various indications. monitoring of the anticoagulant effects. rebound thrombin, and drug interactions. The bleeding complications discussed in some of the earlier trials may be due to the interaction of these drugs with aspirin. Several pharmacological and physical approaches have been tested for the control of bleeding due to thrombin inhibitors.
Thrombin inhibitors and hirudin have a short half-life of about 30--45 minutes. Hence. they may not require an antagonist to neutralize their effects. Fareed et al. 67 have proposed that in normal individuals without any herno-static deficit, hirudin at therapeutic levels should not produce any effect on bleeding. However, considering the indications it is proposed to be used for, an antagonist to neutralize its anticoagulant action may be necessary. An antithrombin antidote may be essential in case of accidental overdose in patients with renal disease. Potential candidates under investigation as possible hirudin antagonists include: di-isopropyl-phosphoryl-thrombin (DIP-thrombin) (68), recombinant factor VIla, I-desamino-8-arginine vasopressin (DDA VP), factor VIII (69). bazotroxobin, ecarin-induced formation of meizothrombin, and activated prothrombin complexes such as factor VIII bypass inhibitor (FEIBA®, Dade. Miami. FL, U.S.A.) (26, (69) (70) (71) (72) (73) (74) (75) (76) . Further studies are needed to evaluate these antidotes for argatroban and related drugs.
Molecular engineering of prothrombin molecules have resulted in the development of a number of variants that lack the procoagulant actions, but can complex with hi-rUdin to neutralize its anticoagulant effects (69) . These recombinant proteins have been found to be effective in the neutralization of the anticoagulant activity of hirudin.
MONITORING OF THROMBIN INHIBITORS
Thrombin inhibitors are of natural, recombinant, and synthetic origin and produce their effect on thrombin as reversible and nonreversible inhibitors. They can be directed against the catalytic site of thrombin or bind to the exosites of thrombin. The mechanism and kinetics of their activity can be readily studied using biochemical methods. However, these are not practical for the monitoring of their effects.
All of the antithrombin agents produce an anticoagulant effect in such global tests as the prothrombin time (PT) and aPTT. In these assays, hirudin is the most potent anticoagulant. Efegatran, argatroban, and hirulog all have similar protiles in the PT and aPTT assays. However. in the Heptest assay argatroban is a stronger anti-Coagulant in comparison to the other two agents. Although each of these agents is capable of producing inhibition of thrombin, the mechanism of their actions is different from each other and, therefore, differences in their prolongation of the clot-based assays may not be an indication of their anticoagulantlantithrombotic potency.
A clot-based assay known as the ecarin clotting time has been recently developed for the specific monitoring of antithrombin agents. Ecarin represents a snake venom (Echis carinatus) that converts prothrombin to meizothhrombin, which eventualIy produces a clotting endpoint in citrated whole blood and' plasma. Each thrombin inhibitor has its own distinct anticoagulant effect in this assay. Hirulog produces the weakest effect. whereas hi-rUdin showed the strongest effect in whole blood. This assay is sensitive to these antithrombin agents and can also be used to monitor their effect in whole blood. It must be stressed that ecarin clotting time primarily measures the absolute concentration of thrombin inhibitors. Its relevance to physiologic effects is limited.
Clot-based assays and the chromogenic substratebased anti-lla assay can also be used to monitor the antithrombin effects of these drugs. However, at low concentrations of some of these agents the anti-lla assay is not capable of measuring the absolute concentration of these antithrombin agents. Thus, this test has a limited sensitivity and in clinical settings it may not be practical in the monitoring of the anticoagulant actions of antithrombin agents.
Some of the enzyme-linked immunosorbent assays (ELlSAs) such as prothrombin fragment FI.2, thrombinantithrombin complex. and fibrinopeptide A (FPA) are capable of measuring the effect of these agents on thrombin at different stages of its activation. These assays may assist in the monitoring of the effect of antithrombin agents. In addition, ELlSAs for absolute drug concentration of hirudin and several other antithrombin agents using monoclonal antibodies to these agents have been developed. Several assays for hirudin are commercialIy available (Stago, Paris, France; American Diagnostica, Greenwich, CT, U.S.A.).
COST CONSIDERATIONS
Only limited information is available on the cost of these thrombin inhibitors. In the case of r-hirudin, cost considerations have only been taken into account for specific indications and a limited database is available on this subject at the present time. Currently. most of the indications for hirudin are the same as for unfractionated heparin or low molecular weight heparins. The cost analysis for various indications must, therefore, be based on site-specific indications such as surgical anticoagulation, prophylaxis, and treatment of DVT and cardiovascular use.
From the standpoint of production cost, r-hirudin is certainly more expensive than the heparins. However, for each of the specific indications, a comprehensive pharmacoeconomic analysis involving the dosage. nursing care, monitoring, and the incidence of adverse reactions and clinical outcome has to be considered. Such a comprehensive analysis may provide different cost values for hirudin and related drugs.
In conjunction with the GUSTO lIb study, a cost analysis from a pharmacoeconomic substudy was performed and reported recently. In this cost analysis, reimbursement was received from 50% of the treated patients. Considering the two deaths and seven myocardial infarctions prevented per 1.000 study patients. it was computed that if the drug was priced at $500. the cost per year of life saved would be around $16.000. If the price of r-hirudin was $1,000, the cost would be $32,000 and for $1,500, the estimated cost would be around $48,000. This information was used to suggest that a cost below $1,500 would be considered cost-effective. This projected cost is much higher than the cost for heparin and other synthetic antithrombin agents. Whether or not the cost calculated on the basis of survival estimate is valid for such comparisons is questionable. If the mortality rates alone were used, then the drug would have to be priced at a much lower level to be cost-effective, with a price of $500 giving a cost per year of life saved of $31,250. The cost analysis based on nonsignificant results such as those reported in the GUSTO lib substudy might not be accurate and additional data is needed.
A cost analysis for the use of r-hirudin for prophylaxis of DVT after hip surgery can be projected based on the recent study published by Eriksson, et al. (63) . In this study, r-hirudin was used in a similar protocol as that used for the low molecular weight heparins. Based on the historic controls where low molecular weight heparin and heparin have been used for post-hip surgical prophylaxis of DVT, the cost of r-hirudin will be three to fivefold higher than the current price for low molecular weight heparin. However, if monitoring and other adverse outcomes are to be included in this analysis, the figures may be different. Similar analysis for DVT therapy and other indications can be performed. Therefore, it is fair to conclude that the cost-effectiveness of r-hirudin use in various indications will require additional analysis. With the ongoing developments with low molecular weight heparin it is likely that these drugs will also be developed for the same indications as thrombin inhibitors. Low molecular weight heparins are relatively weaker anticoagulant drugs; however, these agents exert other effects on the blood and vasculature. It has been claimed that monitoring may not be needed for these agents. These drugs are relatively more expensive than unfractionated heparin. A comparative cost analysis of these agents with thrombin inhibitors is not available at this time. However, it is clear that these agents will be more expensive than heparin for any given indication. The relative cost of thrombin inhibitors for the postsurgical prophylaxis of DVT and the management of coronary syndrome may be higher than low molecular weight heparin. Additional studies are needed to make valid comparisons on this issue and clinical trials may be needed to compare these two classes of drugs. It is clear that in several indications, thrombin inhibitors may be the only choice for managing patients requiring anticoagulation. In some situations cost may not playa factor.
FUTURE TRENDS
The development of thrombin inhibitors has added a new dimension in the management of thrombotic and C/;" AI'!,!l1m'/II!>o.,;.,/I/"/IIo.\·uuis, vot. 5. SU!'!'!. t. !'J'I'J vascular disorders. While the major clinical indications for these agents include interventional cardiovascular procedures and DVT prophylaxis, only limited information is available for their use in the area of surgical and therapeutic anticoagulation. It is expected that many of the newer thrombin inhibitors, such as hirudin and argatroban, will be developed as anticoagulants and can be used as a substitute to heparin in clinically validated indications. Synthetic tripeptides with broader serine protease inhibitory spectra are unique drugs to control thrombogenesis at different levels and may prove to be more useful in chronic indications, including prophylactic usage. These agents can also be developed for potential oral anticoagulation purposes. The usefulness of various thrombin inhibitors in a given medical or surgical indication can only be proven in properly designed clinical trials. Several clinical trials are currently ongoing and will provide useful data to optimize the use of new antithrombin drugs.
In corning years, several newer antithrombin agents with varying degrees of specificity to thrombin and other serine proteases will become available. Beside the inhibition of serine proteases, these agents will also produce effects on blood, vascular, and cellular targets, including several receptor sites. Furthermore, these agents may also have some direct interactions with plasmatic proteins and cellular sites. This may influence their pharmacological profile and clinical outcome. The endogenous transformation of these agents may also play an important role, and the observed clinical effects of the given agents may be strongly inlluenced by this process. Thus, the consequences of endogenous transformations and interactions may have to be assessed for the optimal development of these agents. Thus, each of the thrombin inhibitors should be considered as a distinct drug and the results of only thrombin inhibition in regard to fibrin formation should not be the sole determinant of their actions. Another unresolved issue is related to the metabolic conversion of these agents. No information available on the metabolites and their contribution to the overall antithrombotic actions produced by these agents.
Owing to the defined chemical nature of the thrombin inhibitors, these agents have been coupled with other pharmacological entities to develop hybrid multiple effects. Thus, a bifunctional hybrid to target desired activation sites can be developed. Many of these agents can also be conjugated with inert linker or carrier molecules to obtain desired biological half-life and site specificity. Polyethylene glycol coupled hirudin is currently under clinical development. This drug has an extended half-life and is more potent than hirudin at equivalent antithrombin levels. This introduces the concept of designer antithrombin agents. Biotechnology, organic synthesis, and knowledge of natural products may lead to the development of many molecularly developed antithrombin agents. Despite the development of a desirable molecule With prolonged pharmacodynamics. it must be noted that the coupling groups such as the PEG moieties may also have strong effects. These should be clearly investigated.
Because of multiple sites of action. thrombin inhibitors may exhibit strong drug interactions. It will. therefore. be important to consider these interactions as one of the crucial factors in their clinical development. A systematic investigation on the potential drug interactions of these agents with commonly used drugs in specific indications will be highly desirable since many of the patients who will be treated with these drugs will have on board anti platelet drugs such as aspirin. These agents may also exhibit significant interaction with other drugs such as oral anticoagulants and thrombolytic agents.
Although several agents exhibiting thrombin inhibitory properties will be developed under the classification as antithrombin drugs. it is important to know that this may be only one of many actions of these new drugs. Besides modulating thrombin-mediated functions. these agents will also exhibit secondary and tertiary pharma-Cological effects that will significantly influence their clinical profile. Thus. although a new class of anticoagulant drugs classified as antithrombin agents will emerge. thrombin inhibition will be one of the many pharmacological actions that these agents may exhibit. Thrombin inhibitors may also exhibit significant drug interactions with the anti platelet drugs. In cardiovascular indications their interactions may play an important role.
Beside systemic administration. the newer thrombin inhibitors can also be developed for oral. nonparenteral, and on-site delivery. Furthermore. these agents can be incorporated with biomaterials and formulated for depot delivery. Iontophoresis. phonophoresis, and other delivery modalities can be used to mobilize these agents. Thrombin inhibitors. therefore. provide a wide spectrum of newer anticoagulant and anti thrombotic drugs that can be developed for multiple indications to control thrombosis and related pathophysiologic events. However. it must be understood that these agents are not heparin. each product represents a distinct drug entity and must be developed as a new drug in a given indication. Thus. the safety and efficacy of each of these agents has to be individually evaluated.
At the present time several pharmaceutical companies are in the process of developing thrombin inhibitors for various indications. A list of these companies is given in Table 2 . Revasc® is the trade name of the r-hirudin from Novartis, which will be developed by Sanofi (Paris. France) for DVT prophylaxis under a new licensing agreement. Refludan'" is the trade name of the r-hirudin from Hoechst, which has been approved in Germany as an alternate anticoagulant in HIT syndrome. Polyethylene glycol coupled hirudin is being developed for various coronary indications by Knoll (Ludwigshafen, Germany). Novastan is the only nonhirudin-related antithrombin agent with advanced clinical development in Europe and North America. This drug is presently in clinical use in Japan for stroke and other indications.
Other antithrombin agents such as napsagatran and efegatran are in clinical trials. However. their developmental status is not clear at this time.
Undoubtedly antithrombin agents such as hirudin will be useful in the management of anticoagulation and prophylaxis of DVT in heparin compromised patients. Additional indications may also include cardiovascular and cerebrovascular indications. However. because of their distinct mechanism of action and pharmacodynamic individuality. these agents may not be true substitutes for heparin. Thrombin inhibitors may be useful as anticoagulants for medical and surgical indications. Optimization and monitoring considerations will be important in the development of these drugs. Thus. there should be proper understanding of the activities of thrombin inhibitors and their use should be considered with caution.
